OptiNose (OPTN) Stock On The Rise Before Market Opens Today, Why?

The share price of OptiNose Inc. (NASDAQ: OPTN) climbed 3.71% to trade at $3.92 in premarket trading at last check. Friday’s session closed at $3.57 with a loss of 4.03% for OptiNose stock. OPTN stock has declined by -11.63% over the year, and it has fallen by -5.05% over the week. The OPTN stock price is increasing due to an upcoming quarterly earnings release.

When OPTN is releasing financial results?

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

A specialty pharmaceutical company, OptiNose is dedicated to serving the needs of ENT and allergy specialists. By leveraging the nose for drug delivery, OPTN is poised to change the landscape for a range of underserved conditions including migraine and chronic nasal inflammatory diseases.

Read More

On Wednesday, May 5, 2021, OptiNose will report financial results for its first quarter of 2021, along with updates to its business, announced the Company last week.

  • Also, the OPTN’s leadership team will conduct a conference call for the purpose of discussing financial results and OPTN’s updates.
  • On Wednesday, May 5, 2021, OPTN will hold a conference call at 8:00 a.m. Eastern Time.
  • Further, a telephone replay of the call will be made available until Wednesday, May 12, 20210.
  • Visitors to OPTN’s Investors section will be able to see simultaneous webcasts of the call and presentation.
  • Also, OPTN will provide a replay of the webcast sixty days after the event.

What OPTN aims?

OptiNose (OPTN) created a solution to more reliably and consistently reaches the right places with the right drugs, thereby addressing the limitations of other therapies available. Offices of OPTN are located in the United States and Norway.

Related posts